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ORIGINAL ARTICLE
Concurrent hypofractionated radiotherapy and 5-¯ uorouracil for
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Abstract
Purpose. 5-Fluorouracil (5-FU) has shown radiosensitizing properties in vitro. This paper reports the effects of
radiotherapy and concomitant intravenous 5-FU radiosensitization in the treatment of advanced bone sarcomas.
Subjects/methods. Four patients with large inoperable bone sarcomas (three chondrosarcomas and one ® brosarcoma) were
treated with hypofractionated radiotherapy and concomitant 5-FU bolus injection (300 mg m
2 2) before each fraction of
radiotherapy. A radiation fraction of 5 Gy was given twice a week to a normalized total dose (a /b 5 4 Gy) of 75 Gy.
Results. The regimen was well tolerated, the main toxicity being grade I/II diarrhoea in two cases with pelvic irradiation.
Treatment interruption for 1 week was necessary in two cases with pelvic disease but not in two patients treated for
sarcoma of the extremities. A complete symptomatic relief was obtained in all cases immediately after the third to the ® fth
fraction and the median duration was 10 months. Computed tomography scan documented a partial response in 2/4 cases.
Discussion. Hypofractionated radiotherapy combined with potential lethal damage inhibitors for bone sarcomas requires
further investigation.
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Introduction
Sarcomas of the bone are considered to be radiore-
sistant tumours. The only curative therapy is surgi-
cal resection.
1,2 The role of radical or pre-operative
radiotherapy has been evaluated by several studies
showing a 5-year disease-free survival of 20± 40%.
3,4
Post-operative chemotherapy has also been used in
order to enhance local control and decrease the
distant metastases rate although there is no conclus-
ive evidence of any bene® cial effect.
5 Good results
have been reported for tumours in axial sites that are
considered inoperable and are treated with radio-
therapy or combined radio-chemotherapy.
6,7
Although 5-¯ uorouracil (5-FU) is not effective in
bone sarcomas,
8 it has shown radiosensitizing
properties in vitro, probably by inhibiting the radi-
ation-induced DNA damage repair.
9 Here, we
report preliminary results on four locally advanced
bone sarcomas treated with high dose per fraction




Four patients with locally far advanced bone sarco-
mas were treated with high-dose hypofractionated
radiotherapy and concommitant 5-FU chemo-
therapy. All patients underwent a detailed clinical
and laboratory investigation (including chest
and abdomen computed tomography (CT) scan).
The patient and tumour characteristics are reported
in Table 1. Two patients refused amputation, two
had inoperable tumour (pelvic location). Three
out of four patients had tumour unresponsive to
adriamycin/ifosfamide chemotherapy. The age
of the patients ranged from 31 to 58 years and
the performance status ranged from 2 to 3.
The median tumour dimensions were 13 3 l3 cm.
Three were histologically con® rmed as chondro-
sarcomas and one as ® brosarcoma, the grade being
III for all cases.
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Table 1. Patients and tumour characteristics
No. Age Size Previous Previous
patients sex (years) Histology Grade Location (cm) surgery chemotherapy
1 F 31 ChondroSA III Iliac 15 3 14 Inoperable Adria/Ifo
2 M 50 ChondroSA III Tibia 12 3 10 Refused Adria/Ifo
3 M 58 ChondroSA III Tibia 12 3 10 Refused Adria/Ifo
10 F 45 FibroSA III Iliac 20 3 18 Inoperable No
Adria 5 Adiamycin, Ifo 5 Ifosfamide.
Table 2. Treatment characteristics and response in four locally advanced bone sarcomas. All patients received two 5 Gy
radiotherapy fractions per week and 300 mg m
2 of 5-FU intravenously before each fraction
Duration Overall
No. Dose Fraction (Gy) NTD Symptomatic Response of response survival
patients 3 no. fractions (Gy, a/b5 4) relief rate (months) (months)
1 5 3 10 75 SSR PR 15 15 1
2 5 3 10 75 SSR SD 8 14 (l,b)
3 5 3 10 75 SSR MR 12 12 1
10 5 3 10 75 SSR MR 6 6 (pe)
NTD 5 Normalized total dose, SSR 5 substantial symptomatic relief, PR 5 bidimensional measurements of the
tumour reduced by . 50%, MR 5 reduced by 20± 50%, PD 5 progessive disease, 1 5 still alive, l/b 5 death from
lung/bone metastases, oe5 death from pulmonary embolus.
Treatment
The treatment characteristics are reported in Table
2. All cases were treated with a 6 MV X-ray linear
accelerator and, where feasible, part of the dose was
given with 15± 25 MeV electrons. A CT scan-based
radiotherapy treatment planning was considered for
all cases; 5 Gy were given per fraction twice a week
for a total number of 10 fractions. The normalized
total dose (NTD)
10.11 to both the tumour and nor-
mal tissue was calculated for a /b 5 4 Gy, although
higher values of a /b ratio (4± 10 Gy) have been
reported from radioresponsiveness experiments in
sarcoma cell lines.
12 The tumour NTD was 75 Gy.
An intravenous bolus dose of 300 mg/m
2 of 5-FU
was given 1 h before each fraction of radiotherapy.
Metoclopramide 10 mg was given intravenously
before the injection of 5-FU.
Assessment of acute toxicity followed the WHO
toxicity scale.
13 Full blood count and biochemical
tests were done weekly. Performance status was
assessed every 2 weeks. Assessment of response was
done clinically and with CT scan 4 weeks after the
completion of treatment and 4-monthly thereafter.
Patients were followed bimonthly with clinical
examination, blood tests and chest X-ray.
Results
No severe haematological or organ-speci® c acute
toxicity was observed. Grade I/II skin desquamation
was also observed in all four patients. Grade I
haematological toxicity (neutropenia and/or
anaemia) was observed in 2/4 cases. Diarrhoea
grade I appeared in two patients with pelvic disease
and was well controlled with oral medication. In
these two cases the treatment was interrupted for 1
week. No ® brosis or late sequel has been observed
(6± 18 months after radiotherapy.
The main symptomatology of all four treated
cases was uncontrollable pain and three patients
were under heavy analgesic medication with mor-
phine. Substantial pain relief was obtained in all
four patients immediately after the third to ® fth
fraction and morphine was discontinued. The
median duration of symptomatic control was 10
months. CT scan con® rmed a partial response (50±
95% reduction in two-dimensional measurement) in
2/4 (50%) cases. Figure 1(a) and 1(b) shows a case
of chondrosarcoma of the iliac bone with partial
response 6 months after treatment.
Discussion
Bone sarcomas other than Ewing’s sarcoma are
considered to be relatively radioresistant tumours in
which radical treatment is achieved only when
surgery is applied with or without adjuvant radio-
therapy or chemotherapy. In a recent study from the
Norwegian Radium Hospital,
14 complete tumour
removal was a major prognostic factor. Unfortu-
nately, surgery cannot be applied in bone sarcomas
of the axial skeleton, and pelvic tumour location
requires extensive amputation with severe impact on
the quality of life. In these cases, curative radiother-
apy should be tried as an alternative to surgery. A
40% 5-year actuarial survival has been reported by
Krochak et al.
3 on 38 chondrosarcomas of bone,
treated with conventionally fractionated radiother-Concurrent radiotherapy and 5-fu for bone sarcomas 27
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Fig. 1. A large chondrosarcoma of the iliac bone (a) in a 31-year-old woman treated with 10 fractions of 5 Gy (two fractions per
week) and concurrent 300 mg/m
2 5-FU bolus injection 1 h before radiotherapy. Bidimensional measurements 6 months after the end
of radiatherapy showed 90% reduction of tumour size (b). The patient is alive and disease free 15 months after completion of radiotherapy.
apy. However, tumour size has not been analyzed
and patients with high-grade tumour had a 5-year
survival of 22%.
In the present study, we treated four patients with
locally far advanced high-grade bone sarcomas with
radical radiotherapy. In order to increase the results
of radiotherapy, we used hypofractionation com-
bined with 5-FU radiosensitization. The NTD
was 75 Gy. Partial response was observed in
2/4 patients. Kinsella et al.
7 reported a study on
10 unresectable bone and soft tissue sarcomas
treated with large fraction radiotherapy and
misonidasole radiosensitization. Although no
complete remission was observed, stabilization of
the disease and complete symptomatic relief
was achieved in 7/10 patients. This is in accordance
with our results where a long lasting (. 6 months)
symptomatic relief was obtained in all four cases.
In a recent study, Hug et al.
6 treated seven cases
of bone tumours of the axial skeleton with de® nitive
radiotherapy using a combination of protons
and photons. Local failure was observed in 2/7 cases
showing that a high radiation dose results in
good local control. A high local control rate (7/9
patients) has also been reported by the Standford
Group
15 where intra-arterial 5-bromodeoxyuridine
was given together with hypofractionated radio-
therapy for osteosarcomas. However, extensive local
tissue toxicity was observed, including subcutan-
eous ® brosis, neuropathy and non-healing
traumas.
The optimal way to treat inoperable sarcomas has
not yet been de® ned. It seems that high-dose radio-
therapy offers excellent symptomatic relief and
results in long-term progression-free survival in
about 20% of cases. Distant metastases remain a
main cause of failure in high-grade bone sarcomas.
Our preliminary experience shows that hypofrac-
tionated radiotherapy for bone sarcomas combined
with potential lethal damage inhibitors may have a
role in the control of local disease.
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